- Home
- INCR vs INKT Comparison
INCR vs INKT Comparison
Compare INCR & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- INKT
- Stock Information
- Founded
- INCR 1994
- INKT 2017
- Country
- INCR Israel
- INKT United States
- Employees
- INCR N/A
- INKT N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- INCR Health Care
- INKT Health Care
- Exchange
- INCR Nasdaq
- INKT Nasdaq
- Market Cap
- INCR 78.0M
- INKT 69.2M
- IPO Year
- INCR N/A
- INKT 2021
- Fundamental
- Price
- INCR $1.38
- INKT $12.78
- Analyst Decision
- INCR
- INKT Buy
- Analyst Count
- INCR 0
- INKT 3
- Target Price
- INCR N/A
- INKT $37.50
- AVG Volume (30 Days)
- INCR 24.8K
- INKT 21.2K
- Earning Date
- INCR 10-08-2025
- INKT 11-14-2025
- Dividend Yield
- INCR N/A
- INKT N/A
- EPS Growth
- INCR N/A
- INKT N/A
- EPS
- INCR N/A
- INKT N/A
- Revenue
- INCR $72,158,312.00
- INKT N/A
- Revenue This Year
- INCR $69.54
- INKT N/A
- Revenue Next Year
- INCR $41.75
- INKT N/A
- P/E Ratio
- INCR N/A
- INKT N/A
- Revenue Growth
- INCR N/A
- INKT N/A
- 52 Week Low
- INCR $1.17
- INKT $4.56
- 52 Week High
- INCR $1.79
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- INCR 40.61
- INKT 41.18
- Support Level
- INCR $1.31
- INKT $13.13
- Resistance Level
- INCR $1.43
- INKT $14.20
- Average True Range (ATR)
- INCR 0.06
- INKT 0.70
- MACD
- INCR -0.00
- INKT -0.03
- Stochastic Oscillator
- INCR 37.50
- INKT 35.10
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.